257 related articles for article (PubMed ID: 19920004)
1. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study.
Levine RJ; Vatten LJ; Horowitz GL; Qian C; Romundstad PR; Yu KF; Hollenberg AN; Hellevik AI; Asvold BO; Karumanchi SA
BMJ; 2009 Nov; 339():b4336. PubMed ID: 19920004
[TBL] [Abstract][Full Text] [Related]
2. First trimester serum angiogenic and anti-angiogenic factors in women with chronic hypertension for the prediction of preeclampsia.
Nzelu D; Biris D; Karampitsakos T; Nicolaides KK; Kametas NA
Am J Obstet Gynecol; 2020 Apr; 222(4):374.e1-374.e9. PubMed ID: 31705883
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum levels of soluble fms-like tyrosine kinase-1 and placental growth factor at 20 and 28 weeks of gestational age and the risk of spontaneous preterm birth.
Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
Am J Obstet Gynecol; 2023 Aug; 229(2):164.e1-164.e18. PubMed ID: 36758709
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
[TBL] [Abstract][Full Text] [Related]
5. Prediction of imminent preeclampsia at 35-37 weeks gestation.
Ciobanu A; Wright A; Panaitescu A; Syngelaki A; Wright D; Nicolaides KH
Am J Obstet Gynecol; 2019 Jun; 220(6):584.e1-584.e11. PubMed ID: 30738886
[TBL] [Abstract][Full Text] [Related]
6. Human chorionic gonadotropin, angiogenic factors, and preeclampsia risk: a nested case-control study.
Asvold BO; Eskild A; Vatten LJ
Acta Obstet Gynecol Scand; 2014 May; 93(5):454-62. PubMed ID: 24575980
[TBL] [Abstract][Full Text] [Related]
7. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio.
Buhimschi CS; Baumbusch MA; Dulay AT; Lee S; Wehrum M; Zhao G; Bahtiyar MO; Pettker CM; Ali UA; Funai EF; Buhimschi IA
BJOG; 2010 Feb; 117(3):321-30. PubMed ID: 19943826
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessment.
Maraka S; Mwangi R; McCoy RG; Yao X; Sangaralingham LR; Singh Ospina NM; O'Keeffe DT; De Ycaza AE; Rodriguez-Gutierrez R; Coddington CC; Stan MN; Brito JP; Montori VM
BMJ; 2017 Jan; 356():i6865. PubMed ID: 28122781
[TBL] [Abstract][Full Text] [Related]
9. [Thyroid hormone changes in women with pre-eclampsia and its relationship with the presence of pre-eclampsia].
Zhou J; Du J; Ma B; Liu X; Qiu H; Li J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 2014 Feb; 49(2):109-13. PubMed ID: 24739642
[TBL] [Abstract][Full Text] [Related]
10. Thyroid-stimulating hormone, anti-thyroid antibodies, and pregnancy outcomes.
Plowden TC; Schisterman EF; Sjaarda LA; Perkins NJ; Silver R; Radin R; Kim K; Galai N; DeCherney AH; Mumford SL
Am J Obstet Gynecol; 2017 Dec; 217(6):697.e1-697.e7. PubMed ID: 28917612
[TBL] [Abstract][Full Text] [Related]
11. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic markers and their longitudinal change for predicting adverse outcomes in pregnant women with chronic hypertension.
Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
Am J Obstet Gynecol; 2021 Sep; 225(3):305.e1-305.e14. PubMed ID: 33812812
[TBL] [Abstract][Full Text] [Related]
13. Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis.
Toloza FJK; Derakhshan A; Männistö T; Bliddal S; Popova PV; Carty DM; Chen L; Taylor P; Mosso L; Oken E; Suvanto E; Itoh S; Kishi R; Bassols J; Auvinen J; López-Bermejo A; Brown SJ; Boucai L; Hisada A; Yoshinaga J; Shilova E; Grineva EN; Vrijkotte TGM; Sunyer J; Jiménez-Zabala A; Riaño-Galan I; Lopez-Espinosa MJ; Prokop LJ; Singh Ospina N; Brito JP; Rodriguez-Gutierrez R; Alexander EK; Chaker L; Pearce EN; Peeters RP; Feldt-Rasmussen U; Guxens M; Chatzi L; Delles C; Roeters van Lennep JE; Pop VJM; Lu X; Walsh JP; Nelson SM; Korevaar TIM; Maraka S
Lancet Diabetes Endocrinol; 2022 Apr; 10(4):243-252. PubMed ID: 35255260
[TBL] [Abstract][Full Text] [Related]
14. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop preeclampsia.
Powers RW; Roberts JM; Cooper KM; Gallaher MJ; Frank MP; Harger GF; Ness RB
Am J Obstet Gynecol; 2005 Jul; 193(1):185-91. PubMed ID: 16021077
[TBL] [Abstract][Full Text] [Related]
15. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.
Aggarwal S; Sunderland N; Thornton C; Xu B; Hennessy A; Makris A
Am J Obstet Gynecol; 2017 Feb; 216(2):170.e1-170.e8. PubMed ID: 27793555
[TBL] [Abstract][Full Text] [Related]
17. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
18. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia.
Lynch AM; Murphy JR; Gibbs RS; Levine RJ; Giclas PC; Salmon JE; Holers VM
BJOG; 2010 Mar; 117(4):456-62. PubMed ID: 20074261
[TBL] [Abstract][Full Text] [Related]
19. Predelivery placenta-associated biomarkers and computerized intrapartum fetal heart rate patterns.
Bowe S; Mitlid-Mork B; Gran JM; Distante S; Redman CWG; Staff AC; Georgieva A; Sugulle M
AJOG Glob Rep; 2023 Feb; 3(1):100149. PubMed ID: 36647548
[TBL] [Abstract][Full Text] [Related]
20. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
